AMENDMENT

In the Claims

The following Listing of Claims, in which deleted text appears ~~struck through~~ or in double brackets, *e.g.*, [[eroor]], and inserted text appears underlined, will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1. (Previously Presented) A method of treating disorders of trigeminovascular activation, comprising: administering to a mammal having a disorder of trigeminovascular activation a therapeutically effective amount of an α-aminoamide of formula (I):



(I)

wherein:

A is a $-(CH_2)_m-$ or $-(CH_2)_n-X-$, wherein m is 1 or 2; n is zero, 1 or 2; and X is -O-, -S-or -NH-;

R is a phenyl ring, unsubstituted or substituted by one or two substituents independently selected from halogen, hydroxy, C_1-C_4 alkyl, C_1-C_3 alkoxy and trifluoromethyl;

R_1 is hydrogen or C_1-C_3 alkyl;

R_2 is hydrogen or C_1-C_2 alkyl, unsubstituted or substituted by hydroxy or phenyl; phenyl, unsubstituted or substituted by one or two substituents independently selected from C_1-C_3 alkyl, halogen, hydroxy, C_1-C_2 alkoxy or trifluoromethyl;

R_3 is hydrogen or C_1-C_3 alkyl;

or an optically active isomer, racemic mixture, or pharmaceutically acceptable derivative thereof.

2. (Previously presented) A method according to claim 1, wherein in formula (I):

A is a group selected from $-CH_2-CH_2-$, $-CH_2-O-$, $-CH_2-S-$, $-CH_2-CH_2-O-$;

R is a phenyl ring, unsubstituted or substituted by one or two substituents independently selected from halogen, C_1-C_3 alkyl or a methoxy group; or a thienyl ring;

R_1 is hydrogen or C_1-C_2 alkyl;

R_2 is hydrogen or methyl, unsubstituted or substituted by hydroxy, or phenyl unsubstituted or substituted by C_1-C_2 alkyl, halogen, hydroxy, methoxy or trifluoromethyl; and

R_3 is hydrogen or C_1-C_2 alkyl.

3. (Previously presented) A method according to claim 1, wherein in formula (I):

A is $-CH_2-O-$, $-CH_2-S-$ or $-CH_2-CH_2-$;

R is a phenyl ring, unsubstituted or substituted by one or two halogen atoms;

R_1 is hydrogen;

R_2 is hydrogen or methyl, unsubstituted or substituted by hydroxy or phenyl ring, unsubstituted or substituted by a halogen atom; and

R_3 is hydrogen or methyl.

4. (Previously presented) A method according to claim 1, wherein the α-aminoamide is selected from the group consisting of:

2-(4-benzyloxybenzylamino)propanamide;

2-[4-(2-fluorobenzyloxy)benzylamino]propanamide;

2-[4-(2-chlorobenzyloxy) benzylamino]propanamide;

2-[4-(3-fluorobenzyloxy)benzylamino]propanamide;

2-[4-(3-chlorobenzyloxy)benzylamino]propanamide;

2 -[4-(4-fluorobenzyloxy) benzylamino]propanamide;

2-[4-(2-fluorobenzyloxy)benzylamino]-N-methyl-propanamide;

2-[4-(3-fluorobenzyloxy)benzylamino]-N-methyl-propanamide;

2-[4-(2-fluorobenzyloxy)benzylamino]-3-hydroxy-propanamide;

2-[4-(3-fluorobenzyloxy)benzylamino]-3-hydroxy-propanamide;

2-(4-benzyloxybenzylamino)-3-hydroxy-N-methylpropanamide;

2-[4-(2-fluorobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide;

2-[4-(2-chlorobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide;

2-[4-(3-fluorobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide;

2-[4-(3-chlorobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide;

2-[4-(2-(3-fluorophenyl)ethyl)benzylamino)-propanamide;

2-[4-benzylthiobenzylamino)-propanamide;

2-[4-benzyloxybenzylamino]-3-phenyl-N-methylpropanamide;

2-[4-benzyloxybenzylamino]-N-methylbutanamide;

2-[4-benzyloxybenzylamino]-2-phenyl-acetamide;

2-[4-(2-fluorobenzyloxy)benzylamino]-2-phenyl-acetamide

2-[4-(3-fluorobenzyloxy)benzylamino]-2-phenyl-acetamide;

2-[4-(3-chlorobenzyloxy)benzylamino]-2-phenyl-acetamide;

2-[4-(3 fluorobenzyloxy)benzylamino]-2-(2-fluorophenyl)-acetamide;

2-[4-(3-fluorobenzyloxy)benzylamino]-2-(3-fluorophenyl)-acetamide; and

2-[4-(3-chlorobenzyloxy)benzylamino]-2-(3-fluorophenyl)-acetamide;

or an optically active isomer, racemic mixture, or pharmaceutically acceptable derivative thereof.

5. (Previously presented) A method according to claim 1, wherein the α-aminoamide is selected from the group consisting of:

(S)-(+)-2[4-(3-fluorobenzyloxy)benzylamino]-propanamide,
(S)-(+)-2-[4-(2-fluorobenzyloxy)benzylamino]-propanamide and
(S)-(+)-2-[4-(3-chlorobenzyloxy) benzylamino]-propanamide.

6 – 11. (Canceled)

12. (Previously presented) The method of claim 1, wherein the therapeutically effective amount is from about 0.05 to 20 mg/kg body weight per day.

13. (Previously presented) The method of claim 1, wherein the therapeutically effective amount is from about 0.5 to 10 mg/kg day.

14. (Previously presented) A method of claim 1, wherein the therapeutically effective amount is from about 0.5 to 5 mg/kg day.

15. (Canceled)

16. (Previously presented) The method of claim 5, wherein said α-aminoamide is (S)-(+)-2-[4-(3-fluorobenzyloxy)benzylamino]-propanamide.

17. (Previously presented) The method of claim 5, wherein said α-aminoamide is (S)-(+)-2-[4-(2-fluorobenzyloxy)benzylamino]-propanamide.

18. (Previously presented) The method of claim 5, wherein said α-aminoamide is (S)-(+)-2-[4-(3-chlorobenzyloxy) benzylamino]-propanamide.

19. (Previously presented) The method of claim 1, wherein the mammal is a human.

20. (Previously presented) The method of claim 1, wherein the pharmaceutically acceptable derivative is an acid addition salt.

21. (Previously presented) The method of claim 1, wherein said administering is by oral administration.

22. (Previously presented) The method of claim 1, wherein said administering is by parenteral administration.

23. (Canceled)

24. (New) A method of treating migraine, comprising: administering to a mammal having a migraine a therapeutically effective amount of an α-aminoamide of formula (I):



(I)

wherein:

A is a $-(CH_2)_m-$ or $-(CH_2)_n-X-$, wherein m is 1 or 2; n is zero, 1 or 2; and X is -O-, -S-or -NH-;

R is a phenyl ring, unsubstituted or substituted by one or two substituents independently selected from halogen, hydroxy, C_1-C_4 alkyl, C_1-C_3 alkoxy and trifluoromethyl;

R_1 is hydrogen or C_1-C_3 alkyl;

R_2 is hydrogen or C_1-C_2 alkyl, unsubstituted or substituted by hydroxy or phenyl; phenyl, unsubstituted or substituted by one or two substituents independently selected from C_1-C_3 alkyl, halogen, hydroxy, C_1-C_2 alkoxy or trifluoromethyl;

R_3 is hydrogen or C_1-C_3 alkyl;

or an optically active isomer, racemic mixture, or pharmaceutically acceptable derivative thereof.

25. (New) A method according to claim 24, wherein in formula (I):

A is a group selected from $-CH_2-CH_2-$, $-CH_2-O-$, $-CH_2-S-$, $-CH_2-CH_2-O-$;

R is a phenyl ring, unsubstituted or substituted by one or two substituents independently selected from halogen, C_1-C_3 alkyl or a methoxy group; or a thienyl ring;

R_1 is hydrogen or C_1-C_2 alkyl;

R_2 is hydrogen or methyl, unsubstituted or substituted by hydroxy, or phenyl unsubstituted or substituted by C_1-C_2 alkyl, halogen, hydroxy, methoxy or trifluoromethyl; and

R_3 is hydrogen or C_1-C_2 alkyl.

26. (New) A method according to claim 24, wherein in formula (I):

A is $-CH_2-O-$, $-CH_2-S-$ or $-CH_2-CH_2-$;

R is a phenyl ring, unsubstituted or substituted by one or two halogen atoms;

R_1 is hydrogen;

R_2 is hydrogen or methyl, unsubstituted or substituted by hydroxy or phenyl ring, unsubstituted or substituted by a halogen atom; and

R_3 is hydrogen or methyl.

27. (New) A method according to claim 24, wherein the α-aminoamide is selected from the group consisting of:

2-(4-benzyloxybenzylamino)propanamide;

2-[4-(2-fluorobenzyloxy)benzylamino]propanamide;

2-[4-(2-chlorobenzyloxy) benzylamino]propanamide;

2-[4-(3-fluorobenzyloxy)benzylamino]propanamide;

2-[4-(3-chlorobenzyloxy)benzylamino]propanamide;

2 -[4-(4-fluorobenzyloxy) benzylamino]propanamide;

2-[4-(2-fluorobenzyloxy)benzylamino]-N-methyl-propanamide;

2-[4-(3-fluorobenzyloxy)benzylamino]-N-methyl-propanamide;

2-[4-(2-fluorobenzyloxy)benzylamino]-3-hydroxy-propanamide;

2-[4-(3-fluorobenzyloxy)benzylamino]-3-hydroxy-propanamide;

2-(4-benzyloxybenzylamino)-3-hydroxy-N-methylpropanamide;

2-[4-(2-fluorobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide;

2-[4-(2-chlorobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide;

2-[4-(3-fluorobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide;

2-[4-(3-chlorobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide;

2-[4-(2-(3-fluorophenyl)ethyl)benzylamino)-propanamide;

2-[4-benzylthiobenzylamino)-propanamide;

2-[4-benzyloxybenzylamino]-3-phenyl-N-methylpropanamide;

2-[4-benzyloxybenzylamino]-N-methylbutanamide;

2-[4-benzyloxybenzylamino]-2-phenyl-acetamide;

2-[4-(2-fluorobenzyloxy)benzylamino]-2-phenyl-acetamide

2-[4-(3-fluorobenzyloxy)benzylamino]-2-phenyl-acetamide;

2-[4-(3-chlorobenzyloxy)benzylamino]-2-phenyl-acetamide;

2-[4-(3 fluorobenzyloxy)benzylamino]-2-(2-fluorophenyl)-acetamide;

2-[4-(3-fluorobenzyloxy)benzylamino]-2-(3-fluorophenyl)-acetamide; and

2-[4-(3-chlorobenzyloxy)benzylamino]-2-(3-fluorophenyl)-acetamide;

or an optically active isomer, racemic mixture, or pharmaceutically acceptable derivative thereof.

28. (New) A method according to claim 24, wherein the α-aminoamide is selected from the group consisting of:

(S)-(+)-2[4-(3-fluorobenzyloxy)benzylamino]-propanamide,

(S)-(+)-2-[4-(2-fluorobenzyloxy)benzylamino]-propanamide and

(S)-(+)-2-[4-(3-chlorobenzyloxy) benzylamino]-propanamide.

29. (New) A method according to claim 24, wherein said migraine is migraine with visual aura.

30. (New) The method of claim 24, wherein the therapeutically effective amount is from about 0.05 to 20 mg/kg body weight per day.

31. (New) The method of claim 24, wherein the therapeutically effective amount is from about 0.5 to 10 mg/kg day.

32. (New) A method of claim 24, wherein the therapeutically effective amount is from about 0.5 to 5 mg/kg day.

33. (New) The method of claim 28, wherein said α-aminoamide is (S)-(+)-2-[4-(3-fluorobenzyloxy)benzylamino]-propanamide.

34. (New) The method of claim 28, wherein said α-aminoamide is (S)-(+)-2-[4-(2-fluorobenzyloxy)benzylamino]-propanamide.

35. (New) The method of claim 28, wherein said α-aminoamide is (S)-(+)-2-[4-(3-chlorobenzyloxy) benzylamino]-propanamide.

36. (New) The method of claim 28, wherein the mammal is a human.

37. (New) The method of claim 28, wherein the pharmaceutically acceptable derivative is an acid addition salt.

38. (New) The method of claim 28, wherein said administering is by oral administration.

39. (New) The method of claim 28, wherein said administering is by parenteral administration.